AR045654A1 - Formas cristalinas de acido r-(r*,r*)-2-(4- fluorofenil) - , dihidroxi - 5-(1- metiletil)- 3- fenil- 4-( fenilamino) - carbonil- 1h- pirrol-1- heptanoico - Google Patents
Formas cristalinas de acido r-(r*,r*)-2-(4- fluorofenil) - , dihidroxi - 5-(1- metiletil)- 3- fenil- 4-( fenilamino) - carbonil- 1h- pirrol-1- heptanoicoInfo
- Publication number
- AR045654A1 AR045654A1 ARP040103296A ARP040103296A AR045654A1 AR 045654 A1 AR045654 A1 AR 045654A1 AR P040103296 A ARP040103296 A AR P040103296A AR P040103296 A ARP040103296 A AR P040103296A AR 045654 A1 AR045654 A1 AR 045654A1
- Authority
- AR
- Argentina
- Prior art keywords
- methylethyl
- fluorophenyl
- phenyl
- heptanoic
- dihydroxi
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Se describen nuevas formas cristalinas de ácido [R-(R*, R*)]-2-(4-fluorofenil)-beta, gamma-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1H-pirrol-1-heptanoico (ácido libro atorvastatina) designadas Forma A y forma B, caracterizada por su patrón de difracción de rayos X en polvo y sus espectros NMR en estado sólido, así como métodos para la preparación y composición farmacéutica de las mismas, que son útiles como agentes para el tratamiento de hiperlipidemia, hipercolesterolemia, osteoporosis, hiperplasia protática benigna, y enfermedad de alzhemer, y para prepara sales de atorvastatina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50359203P | 2003-09-17 | 2003-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR045654A1 true AR045654A1 (es) | 2005-11-02 |
Family
ID=34312443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040103296A AR045654A1 (es) | 2003-09-17 | 2004-09-15 | Formas cristalinas de acido r-(r*,r*)-2-(4- fluorofenil) - , dihidroxi - 5-(1- metiletil)- 3- fenil- 4-( fenilamino) - carbonil- 1h- pirrol-1- heptanoico |
Country Status (16)
Country | Link |
---|---|
US (1) | US20070276027A1 (es) |
EP (1) | EP1663969A1 (es) |
JP (1) | JP2007505885A (es) |
KR (1) | KR100781420B1 (es) |
CN (2) | CN101318923A (es) |
AR (1) | AR045654A1 (es) |
AU (1) | AU2004272365A1 (es) |
BR (1) | BRPI0414457A (es) |
CA (1) | CA2539158A1 (es) |
IL (1) | IL173651A0 (es) |
MX (1) | MXPA06003003A (es) |
NO (1) | NO20060716L (es) |
RU (1) | RU2315755C2 (es) |
TW (1) | TW200524862A (es) |
WO (1) | WO2005026116A1 (es) |
ZA (1) | ZA200602222B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100023059A (ko) | 2005-12-13 | 2010-03-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법 |
KR20090128423A (ko) * | 2007-04-13 | 2009-12-15 | 니콕스 에스. 에이. | 아토르바스타틴 4-(니트록시)부틸 에스테르의 결정형 |
WO2010080971A1 (en) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Crystalline polymorphic forms of an antidiabetic compound |
CA2706270C (en) * | 2010-06-03 | 2020-01-07 | Accucaps Industries Limited | Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation |
CA3065589C (en) | 2010-06-03 | 2022-04-26 | Catalent Ontario Limited | Multi phase soft gel capsules, apparatus and method thereof |
KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
US5124482A (en) * | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
US5216174A (en) * | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5245047A (en) * | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5149837A (en) * | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5097045A (en) * | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5248793A (en) * | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5103024A (en) * | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5155251A (en) * | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
US5213995A (en) * | 1992-04-16 | 1993-05-25 | At&T Bell Laboratories | Method of making an article comprising a periodic heteroepitaxial semiconductor structure |
DK0680320T3 (da) * | 1993-01-19 | 1999-10-25 | Warner Lambert Co | Stabilt oralt CI-981-præparat og fremgangsmåde til fremstilling deraf |
US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
WO1997003959A1 (en) * | 1995-07-17 | 1997-02-06 | Warner-Lambert Company | Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
IL127058A (en) * | 1996-07-29 | 2001-07-24 | Warner Lambert Co | Process for the synthesis of protected esters of acid (S) - 4,3 dehydroxybutyric |
AU755543B2 (en) * | 1997-12-19 | 2002-12-12 | Warner-Lambert Export Limited | Process for the synthesis of 1,3-diols |
SI20070A (sl) | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Nove soli inhibitorjev HMG-CoA reduktaze |
ES2313999T3 (es) * | 2000-11-16 | 2009-03-16 | Teva Pharmaceutical Industries Ltd. | Hidrolisis de esteres del acido (r(r*,r*))-2-(4-fluorofenil)-beta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico con hidroxido calcico. |
US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
-
2004
- 2004-09-06 CN CNA2008101341489A patent/CN101318923A/zh active Pending
- 2004-09-06 JP JP2006526717A patent/JP2007505885A/ja active Pending
- 2004-09-06 MX MXPA06003003A patent/MXPA06003003A/es unknown
- 2004-09-06 WO PCT/IB2004/002919 patent/WO2005026116A1/en active Application Filing
- 2004-09-06 BR BRPI0414457-0A patent/BRPI0414457A/pt not_active IP Right Cessation
- 2004-09-06 EP EP04769318A patent/EP1663969A1/en not_active Withdrawn
- 2004-09-06 RU RU2006108385/04A patent/RU2315755C2/ru not_active IP Right Cessation
- 2004-09-06 US US10/572,324 patent/US20070276027A1/en not_active Abandoned
- 2004-09-06 CA CA002539158A patent/CA2539158A1/en not_active Abandoned
- 2004-09-06 AU AU2004272365A patent/AU2004272365A1/en not_active Abandoned
- 2004-09-06 KR KR1020067005316A patent/KR100781420B1/ko not_active IP Right Cessation
- 2004-09-06 CN CNA2004800269756A patent/CN1852894A/zh active Pending
- 2004-09-15 AR ARP040103296A patent/AR045654A1/es unknown
- 2004-09-15 TW TW093127885A patent/TW200524862A/zh unknown
-
2006
- 2006-02-09 IL IL173651A patent/IL173651A0/en unknown
- 2006-02-14 NO NO20060716A patent/NO20060716L/no not_active Application Discontinuation
- 2006-03-16 ZA ZA200602222A patent/ZA200602222B/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2315755C2 (ru) | 2008-01-27 |
EP1663969A1 (en) | 2006-06-07 |
CN1852894A (zh) | 2006-10-25 |
KR20060037467A (ko) | 2006-05-03 |
TW200524862A (en) | 2005-08-01 |
IL173651A0 (en) | 2006-07-05 |
ZA200602222B (en) | 2007-07-25 |
CN101318923A (zh) | 2008-12-10 |
RU2006108385A (ru) | 2006-08-10 |
WO2005026116A1 (en) | 2005-03-24 |
JP2007505885A (ja) | 2007-03-15 |
US20070276027A1 (en) | 2007-11-29 |
KR100781420B1 (ko) | 2007-12-03 |
BRPI0414457A (pt) | 2006-11-14 |
CA2539158A1 (en) | 2005-03-24 |
MXPA06003003A (es) | 2006-06-23 |
AU2004272365A1 (en) | 2005-03-24 |
NO20060716L (no) | 2006-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR003458A1 (es) | Forma cristalina de atorvastatina o hidrato de la misma y composicion farmaceutica que la comprende. | |
WO2005105738A3 (en) | Salt forms of atorvastatin | |
RS100003A (en) | Crystalline forms of /r-(r*,r*)-2-(4- fluorphenyl)-beta,delta -dihydroxy-5(1- methylethyl)-phenyl-4-/phenylamino) carbonyl/-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) | |
ATE207465T1 (de) | Kristalline form iii des hemi calcium salzes von (r-(r*,r*))-2-(4-fluorphenyl)-beta-delta- dihydroxy-5-(1-methylethyl)-3-phenyl-4- ((phenylamino)carbonyl)-1h-pyrrol-1-heptansäure (atorvastatin) | |
DK0839132T5 (da) | Fremgangsmåde til fremstilling af amorft [R-(R*,R*)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyrecalciumsalt (2:1) | |
BR0116785A (pt) | Processo para a sìntese da forma v de atorvastatina e fenilboronatos como compostos intermediários | |
NZ533935A (en) | Crystalline [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-heptanoic acid calcium salt (2:1) | |
TW200738624A (en) | Novel forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium | |
AR045654A1 (es) | Formas cristalinas de acido r-(r*,r*)-2-(4- fluorofenil) - , dihidroxi - 5-(1- metiletil)- 3- fenil- 4-( fenilamino) - carbonil- 1h- pirrol-1- heptanoico | |
WO2006011041A3 (en) | Crystalline forms of (r-(r*))-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-hept anoic acid calcium salt (2:1) | |
BRPI0417138A (pt) | n-alquil-pirroles como inibidores de hmg-coa-redutase | |
HUP0600120A2 (en) | New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it | |
CA2522899A1 (en) | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) | |
IS7019A (is) | Kristallaform af 'R-(R*,R*)!-2-(4-flúorfenýl)-beta, delta-díhýdroxý-5-(1-metýletýl)-3-fenýl-4-'fenýlamínó)karbónýl!-1H-pýrról-1-heptansýru kalsíum salt (2:1) (atorvastatín) | |
CY1110165T1 (el) | Νεες μορφες αλατος μαγνησιου του [r-(r*,r*)]-2-(4-φθοροφαινυλ)-β,β-διυδροξυ-5-(1-μεθυλαιθυλ)-3-5 φαινυλ-4-[(φαινυλαμινο)καρβονυλ]-1η-πυρρολο-1-επτανοϊκου οξεος | |
UY27608A1 (es) | Formas cristalinas hidratadas de atorvastatina forma ii y forma iv. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |